In the final instalment of a three-part analysis of Australia’s legal cannabis landscape, Cannabiz chief correspondent Steve Jones examines the reasons behind the declining valuation of the industry’s listed enterprises.

Join the Cannabiz revolution

Want to stay ahead of the cannabis curve with the latest local and international news, analysis and intelligence and access to Australia's legal cannabis industry?

This article is included with our Premium subscription.

Join or login

In January 2018, buoyed by government clearance to export medicinal cannabis from Australia, Cann Group shares soared past $4.

Steve has reported for a number of consumer and B2B titles over a journalism career spanning more than three decades. He is a regulator contributor to health journal, The Medical Republic, writing on...